GlaxoSmithKline Bribery Scandal: Sexual Favors to Increase Sales?
July 18, 2013
China continues to step up its probe into alleged bribery by British drugmaker GlaxoSmithKline to illegally boost sales and inflate the price of its medicines.
Latest from cGMPs
Key considerations for CGMP raw materials compliance
Intas hit with FDA warning letter
Beyond ‘good’ practices
Biocon hit with multiple 483s
Developing a cell and gene therapy packaging strategy
Toward a collaborative pharma ecosystem
Load More Content